Eurofins Scientific Shares Slide Below €58, Down 15.5% Over Three Months
Eurofins Scientific shares fell by 2.85% to €57.34 in early afternoon trading, while the CAC 40 index declined by 0.76% during the session. The stock of the bioanalytical services specialist continues its downward trend following the end-of-April quarterly earnings release. Over three months, the decline has reached 15.53%.
The price of Eurofins Scientific is now trading below the lower Bollinger band, set at €59.36. This configuration indicates potential overselling after a prolonged slide. The RSI at 39 remains below the 50 mark without reaching the low zone of 30. The stock is moving away from its 50-day (€64.87) and 200-day (€63.86) moving averages, which are now well above the current price. The next identified support level is at €60.76, already breached during the session.
Trajectory Hampered Since April Quarterly Report
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The decline follows the publication of the first-quarter results on April 22, which led to a 10.78% drop in the stock on the same day. The company reported organic growth of 2.5%, hindered by adverse weather conditions in North America and the rationalization of unprofitable contracts. The company reaffirmed its organic growth targets for 2026 during this announcement. In mid-April, Eurofins also signed off on the sale of its MET Labs division to UL Solutions for €575 million, as part of a focus on life testing. The financial calendar points to the annual general meeting on May 27, followed by the half-year results on September 18.
SectorSanté · Vaccins et laboratoires de recherche›Services médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1789M€
Guidance from the release
Eurofins a rencontré des vents contraires importants et temporaires.
Malgré une croissance organique modérée, la rentabilité et les marges progressent.
Risks mentioned
Baisse de la demande en raison de conditions climatiques défavorables en Amérique du Nord.
Rationalisation des contrats dans les diagnostics cliniques en Espagne et en Italie.
Opportunities identified
Lancement de nouveaux contrats renforçant notre portefeuille BioPharma.
Initiatives de digitalisation et amélioration du réseau de laboratoires.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
